Swapnil Hiremath :renal: MD<p><a href="https://med-mastodon.com/tags/RCTs" class="mention hashtag" rel="tag">#<span>RCTs</span></a> in the <a href="https://med-mastodon.com/tags/VascularAccess" class="mention hashtag" rel="tag">#<span>VascularAccess</span></a> field are uncommon </p><p>in 2020 we discussed drug coated balloons <a href="http://www.nephjc.com/news/drugcoatedballoon" target="_blank" rel="nofollow noopener noreferrer" translate="no"><span class="invisible">http://www.</span><span class="ellipsis">nephjc.com/news/drugcoatedball</span><span class="invisible">oon</span></a> on <a href="https://med-mastodon.com/tags/NephJC" class="mention hashtag" rel="tag">#<span>NephJC</span></a> </p><p>Now there is this large RCT <a href="https://www.kidney-international.org/article/S0085-2538(23)00182-5/fulltext" target="_blank" rel="nofollow noopener noreferrer" translate="no"><span class="invisible">https://www.</span><span class="ellipsis">kidney-international.org/artic</span><span class="invisible">le/S0085-2538(23)00182-5/fulltext</span></a></p><p>- industry funded<br />- expensive stents<br />- effect on AVF patency (left) much less impressive than target lesion patency (right)</p>